Skip to main content
Fig. 3 | Virology Journal

Fig. 3

From: Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C

Fig. 3

Flow chart of the participants and the outline of study. Among resistance-associated variants (RAVs) negative patients, 72 patients who agreed to start daclatasvir plus asunaprevir (DCV + ASV) therapy were analyzed for treatment response. Virologic response was determined if a level of serum HCV RNA is less than lower limit of quantification (LLOQ)

Back to article page

Virology Journal

ISSN: 1743-422X